Althea Technologies, Inc. has acquired the assets and portfolio of Altus Pharmaceuticals. Altus’ portfolio includes its Cross Linked Enzyme Crystal (CLEC) and controlled release injectable technologies for applications ranging from therapeutics to protein purification and catalysis. The controlled release injectable technology involves protein crystallization and complexation using customized manufacturing equipment installed at Althea.

Additional assets include a portfolio of product candidates including a seven day controlled release growth hormone injectable currently in Phase II trials. Althea manufactures the clinical supplies for this product candidate andAltheaplans to enter into licensing agreeements for these product candidates.

“We are delighted to acquire this portfolio of technologies which complements our core expertise in protein formulation and will bring added value to our customers’ projects,” commented Dr. Shabbir Anik, chief executive officer of Althea Technologies. “We expect multiple applications for a broad range of proteins, peptides and vaccines addressing the need for controlled release, high concentration formulations, and stability.”